China’s Infant Formula Regulatory Updates — Key Takeaways
China’s infant formula market, the largest in the world, has undergone a seismic regulatory transformation. The enforcement of the New National Standard (新国标, xīn guó biāo) under the supervision of the State Administration for Market Regulation (SAMR, 国家市场监督管理总局) has reshaped the competitive landscape, pushing out weaker players and demanding higher scientific rigor from all brands. For foreign executives, understanding these changes is not optional—it is critical for market access and sustained profitability in China.
What is China’s Infant Formula Regulatory Overhaul? This refers to the mandatory implementation of the GB 10765-2021, GB 10766-2021, and GB 10767-2021 standards, which replace the 2010 versions. These regulations govern the composition, labeling, and registration renewal of all infant (Stage 1), follow-on (Stage 2), and toddler (Stage 3) formulas sold in China. Key Number: Over 1,000 formula registrations had been approved under the new standard as of late 2024, a drastic consolidation from over 2,000 products previously registered. This 50% reduction in SKUs signals a clear strategic intent by Beijing to prioritize quality and large-scale R&D capability over market fragmentation.
The Core Mandates: What the New National Standard (新国标) Requires
The 新国标 is explicitly designed to bring infant formula closer to the composition of breast milk. This is not merely a technical adjustment; it is a fundamental shift in product philosophy. The most impactful mandate is the strict regulation of carbohydrates. For Stage 1 and Stage 2 formulas, lactose must be the sole carbohydrate source. Sucrose, fructose, and honey are now explicitly banned for infants under 12 months.
Another critical mandate targets DHA (docosahexaenoic acid). Under the old standard, DHA was optional. The new standard sets a mandatory minimum of 3.6 mg per 100 kJ for all Stage 1 formulas, with a strict upper limit to prevent over-supplementation. This forces formulators to invest heavily in stable, high-quality oil blends. Furthermore, the standards mandate that any “optional” ingredients added for marketing purposes—such as probiotics, MFGM, or HMOs—must be supported by robust Chinese clinical evidence, effectively ending the era of “ingredient hopping” for marketing advantage.
Market Shakeout: Winners, Losers, and Strategic Implications
The registration renewal process has acted as a powerful market cleanser. Domestic giants like Feihe (飞鹤), Yili (伊利), and Junlebao (君乐宝) have emerged as the clear winners. Having invested heavily in R&D and compliant supply chains years in advance, they now command over 70% of the domestic market share by volume. The top three domestic brands alone account for an estimated 50%+ of total sales, a consolidation trend that mirrors the regulatory intent.
Foreign brands have faced a more challenging path. While global leaders like Nestlé, Danone, and Abbott have secured approvals for their key SKUs, the process has been costly and time-consuming. The requirement for SAMR to conduct on-site audits of overseas production facilities, combined with the need to reformulate products to meet China-specific carbohydrate and protein standards (which often differ from Codex Alimentarius), has created significant delays. Smaller foreign niche brands without dedicated China regulatory teams have largely been delisted from the formal channel.
| Parameter | Old Standard (GB 10765-2010) | New Standard (GB 10765-2021) | Strategic Impact |
|---|---|---|---|
| Carbohydrate Source (Stage 1) | Lactose preferred; sucrose/fructose allowed in limited amounts | Lactose mandatory; sucrose, fructose, and honey banned | Increases cost of raw materials; eliminates cheap bulking agents |
| DHA Requirement | Optional (0.2% of total fatty acids recommended) | Mandatory minimum of 3.6 mg/100 kJ | Requires specialized lipid technology; increases microencapsulation costs |
| Protein Content (per 100 kJ) | 0.45 g – 0.70 g | 0.43 g – 0.60 g (Lowered to mimic breast milk) | Requires precision in dairy sourcing; prevents renal overload in infants |
| Optional Ingredients (HMOs, Probiotics) | Self-affirmation by manufacturer | Strict clinical evidence required for health claims | Raises the barrier for marketing innovation; favors firms with strong R&D |
| Registration Renewal Timeline | One-time registration (2016-2018) | Renewal required by 2023-2025; ongoing cycle | Creates a recurring regulatory risk and cost burden |
Renewal Deadlines and the “Grandfathering” Cliff
Executives must understand the hard deadlines. The SAMR ruled that from February 22, 2023, no infant formula could be produced in China or imported under the old standard. However, a critical nuance exists regarding the sell-through of existing stock. Products manufactured before the deadline could be sold until their expiry date, creating a long tail of old-stock inventory that depressed prices through 2024.
For foreign executives, the risk is the “grandfathering cliff.” If your registration certificate expires and the renewal application is not submitted at least 12 months in advance, your product effectively disappears from the Chinese market. Given the SAMR’s processing times and the requirement for facility audits, any delay can result in a multi-year market absence. We estimate that compliance costs per SKU have increased by 20-30% due to the need for clinical trials, upgraded testing laboratories, and regulatory consulting fees.
- Production Cutoff: February 22, 2023 (All new production must meet 新国标).
- Sell-Through Period: Products produced before the cutoff can be sold until the expiration date printed on the can.
- Renewal Window: Certificates must be renewed every 5 years. SAMR recommends starting the renewal process 18 months prior to expiry.
- Cost Impact: R&D and compliance costs have risen by an estimated 20-30% per registered SKU.
